# ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

> **NCT06339658** · — · RECRUITING · sponsor: **Hospital Universitari de Bellvitge** · enrollment: 43 (estimated)

## Conditions studied

- Breast Cancer
- Axillary Metastases

## Interventions

- **PROCEDURE:** Targeted axillary dissection (TAD) by ICG
- **PROCEDURE:** Targeted axillary dissection (TAD) by Blue patent

## Key facts

- **NCT ID:** NCT06339658
- **Lead sponsor:** Hospital Universitari de Bellvitge
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06339658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06339658, "ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06339658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*